Man Group
SRPT icon

Man Group’s Sarepta Therapeutics SRPT Stock Holding History

Man Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.15M Buy
398,144
+362,905
+1,030% +$6.86M 0.01% 948
2026
Q1 		$767K Buy
+35,239
New +$682K ﹤0.01% 1926
2025
Q2 		– Sell
-14,001
Closed -$894K – 2373
2025
Q1 		$894K Buy
+14,001
New +$1.47M ﹤0.01% 1613
2024
Q4 		– Sell
-311,338
Closed -$38.9M – 2189
2024
Q3 		$38.9M Sell
311,338
-75,086
-19% -$10.4M 0.1% 256
2024
Q2 		$61.1M Buy
386,424
+266,419
+222% +$34.2M 0.15% 153
2024
Q1 		$15.5M Buy
+120,005
New +$14.7M 0.04% 519
2023
Q1 		– Sell
-81,744
Closed -$10.6M – 1780
2022
Q4 		$10.6M Buy
81,744
+10,344
+14% +$1.2M 0.04% 541
2022
Q3 		$7.89M Buy
+71,400
New +$7.2M 0.04% 563
2022
Q2 		– Sell
-16,519
Closed -$1.22M – 1681
2022
Q1 		$1.29M Buy
+16,519
New +$1.27M ﹤0.01% 1312
2021
Q4 		– Sell
-31,819
Closed -$2.94M – 2097
2021
Q3 		$2.94M Buy
31,819
+14,063
+79% +$1.08M 0.01% 1046
2021
Q2 		$1.38M Buy
17,756
+7,498
+73% +$568K ﹤0.01% 1318
2021
Q1 		$765K Buy
10,258
+22
+0.2% +$2.03K ﹤0.01% 1362
2020
Q4 		$1.75M Sell
10,236
-30,177
-75% -$4.47M 0.01% 1249
2020
Q3 		$5.68M Sell
40,413
-2,038
-5% -$310K 0.02% 746
2020
Q2 		$6.81M Buy
+42,451
New +$5.78M 0.03% 525
2019
Q4 		– Sell
-17,254
Closed -$1.3M – 1908
2019
Q3 		$1.3M Sell
17,254
-14,446
-46% -$1.71M ﹤0.01% 1371
2019
Q2 		$4.82M Sell
31,700
-8,082
-20% -$982K 0.02% 965
2019
Q1 		$4.74M Buy
39,782
+37,282
+1,491% +$4.79M 0.02% 952
2018
Q4 		$273K Sell
2,500
-6,435
-72% -$805K ﹤0.01% 1756
2018
Q3 		$1.44M Buy
8,935
+6,435
+257% +$880K 0.01% 1528
2018
Q2 		$330K Buy
+2,500
New +$236K ﹤0.01% 1900

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Man Group's SRPT Position: Q2 2026 in Review

Man Group increased its Sarepta Therapeutics (SRPT) stake by 1,030% in Q2 2026, buying an estimated $6.86M and bringing the position to 398,144 shares worth $7.15M. The position accounts for 0.01% of the portfolio, ranked #948.

Man Group first reported a position in SRPT in Q2 2018 and has held it in 21 quarters since. The position peaked at $61.1M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Man Group held 398,144 shares of Sarepta Therapeutics worth $7.15M as of Q2 2026.
  • Man Group bought 362,905 Sarepta Therapeutics shares in Q2 2026, an estimated $6.86M.
  • Sarepta Therapeutics made up 0.01% of Man Group's portfolio in Q2 2026, its #948 holding.
  • Man Group first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • Man Group's Sarepta Therapeutics position peaked at $61.1M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.